Drug companies, including insulin maker Eli Lilly, thought so, too, but GLP-1 turned out to be an impractical medicine: Once injected into the body, it degrades quickly.
The next phase of targeted treatment will likely involve nanoparticles smaller-than-microscopic transport vehicles that are injected into the body and deliver their devastating payload only to a cancerous tumor.